Strategies for optimizing combinations of molecularly targeted anticancer agents

Nature Reviews Drug Discovery

Volumn 5, Issue 8, 2006, Pages 649-659

  Dancey, Janet E ^a   Chen, Helen X ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABT 888; AEG 35156; AEG 357156; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CEP 701; CETUXIMAB; CYTOTOXIC AGENT; DASATINIB; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; GX 15 070; IMATINIB; INO 1001; ISOSORBIDE; METALLOPROTEINASE INHIBITOR; MIDOSTAURIN; OBLIMERSEN; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; LUNG CANCER; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STANDARDIZATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; NEOPLASMS;

EID: 33746622984     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2089     Document Type: Review

References (64)

1. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
2. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
3. Mass, R. D. et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240-246 (2005).
4. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
5. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
6. Sandler, A. B. et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial- E4599. J. Clin. Oncol. 24, A4 (2005).
7. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
8. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
9. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J. Clin. Oncol. 22, 777-784 (2004).
10. Herbst, R. S. et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
11. Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B. & Forastiere, A. A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23, 8646-8654 (2005).
12. Hirte, H. et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol. 24 Jan 2006 [epub ahead of print].
13. Moore, M. J. et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296-3302 (2003).
14. Shepherd, F. A. et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20, 4434-4439 (2002).
15. Sparano, J. A. et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22, 4683-4690 (2004).
16. Kirkwood, J. M. et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). J. Clin. Oncol. 24, A7506 (2005).
17. De Soto, J. A., Bowen, D., Davis, J. H., Southerland, W. M. & Hawkins, M. Jr. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. AntiCancer Res. 22, 1007-1009 (2002).
18. Osborne, C. K., Kitten, L. & Arteaga, C. L. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J. Clin. Oncol. 7, 710-717 (1989).
19. Albain, K. et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol. 21, A143 (2002).
20. Friedman, H. S. et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst. 84, 1926-1931 (1992).
21. 6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16, 3570-3575 (1998).
22. 6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 60, 6307-6310 (2000).
23. Jagtap, P. & Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Rev. Drug Discov. 4, 421-440 (2005).
24. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
25. Haince, J. F., Rouleau, M., Hendzel, M. J., Masson, J. Y. & Poirier, G. G. Targeting poly(ADP-ribosyl)ation: A promising approach in cancer therapy. Trends Mol. Med. 11, 456-463 (2005).
26. Posadas, E. M. et al. Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors - early results from a Phase I study of sorafenib (BAY 43-9006) and bevacizumab. Eur. J. Cancer 3 (Suppl.), A1450 (2005).
27. Saltz, L. B. et al. Randomized Phase II trial of cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 24, A3508 (2005).
28. Moulder, S. L. & Arteaga, C. L. A Phase I/II trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clin. Breast Cancer 4, 142-145 (2003).
29. Hainsworth, J. D. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005).
30. Herbst, R. S. et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent nonsmall-cell lung cancer. J. Clin. Oncol. 23, 2544-2555 (2005).
31. Genentech, Inc. Genentech announces preliminary results from randomized Phase II trial of Avastin and Tarceva in kidney cancer. Press Release October [online], (2005).
32. Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65-72 (2002).
33. Warburton, C. et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin. Cancer Res. 10, 2512-2524 (2004).
34. Baselga, J. et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 23, 5323-5333 (2005).
35. Abd El-Rehim, D. M. et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91, 1532-1542 (2004).
36. Bhargava, R. et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18, 1027-1033 (2005).
37. Bianchi, S. et al. ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. J. Cell Physiol. 206, 702-708 (2006).
38. Kelland, L. R. Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827-836 (2004).
39. Shinn, C., Larsen, D. & Suarez, J. R. Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding. Blood 96, 294b (2000).
40. Gitler, M. S., Monks, A. & Sausville, E. A. Preclinical models for defining efficacy of drug combinations: Mapping the road to the clinic. Mol. Cancer Ther. 2, 929-932 (2003).
41. Reynolds, C. P. & Maurer, B. J. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 110, 173-183 (2005).
42. Tallarida, R. J. Drug synergism: Its detection and applications. J. Pharmacol. Exp. Ther. 298, 865-872 (2001).
43. Teicher, B. A. Assays for in vitro and in vivo synergy. Methods Mol. Med. 85, 297-321 (2003).
44. Chou, T. C. Drug combinations: From laboratory to practice. J. Lab. Clin. Med. 132, 6-8 (1998).
45. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res. 6, 4110-4118 (2000).
46. Meco, D. et al. Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies. Cancer Chemother. Pharmacol. 52, 131-138 (2003).
47. Tan, M., Fang, H. B., Tian, G. L. & Houghton, P. J. Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat. Med. 22, 2091-2100 (2003).
48. Engelholm, S. A. et al. Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. Eur. J. Cancer Clin. Oncol. 21, 815-824 (1985).
49. Ferguson, P. J. & Cheng, Y. C. Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res. 49, 1148-1153 (1989).
50. Smith, A., van Haaften-Day, C. & Russell, P. Sequential cytogenetic studies in an ovarian cancer cell line. Cancer Genet. Cytogenet. 38, 13-24 (1989).
51. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
52. Voskoglou-Nomikos, T., Pater, J. L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227-4239 (2003).
53. Ciardiello, F. et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 10, 784-793 (2004).
54. Jones, H. E. et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 11, 793-814 (2004).
55. Solit, D. B. et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin. Cancer Res. 11, 1983-1989 (2005).
56. Kaelin, W. G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nature Rev. Cancer 5, 689-698 (2005).
57. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977-7982 (2003).
58. Moore, M. J. et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J. Clin. Oncol. ASCO Ann. Mtg Proc. 23, A1 (2005).
59. Miller, K. et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: A randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) Eur. J. Cancer Suppl. ECCO 13 Abstract Book 3, 77 A275 (2005).
60. Miller, K. D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799 (2005).
61. Tabernero, J. et al. Combined anti-EGFR blockade: A Phase I pharmacokinetic and molecular pharmacodynamic study of cetuximab (Erbitux) and gefitinib (Iressa) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR. Clin. Cancer Res. 11 8990s Abs. A107 (2005).
62. Milton, D. T. et al. Phase I/II trial of gefitinib and RAD001 (Everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 24, A7104 (2005).
63. Reardon, D. A. et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 12, 860-868 (2006).
64. Britten, C. D. et al. Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2 + breast cancer. J. Clin. Oncol. 22, A3045 (2004)